(PRESS RELEASE) Neurotrack, maker of innovative digital cognitive assessments, announced today that Co-founder and CEO Elli Kaplan will participate in two upcoming speaking events on developments in cognitive care and related technology.
On October 16, 2024 at 10 am PT/1 pm ET, Elli will be a featured guest on a webinar for the Network for Excellence in Health Innovation (NEHI) entitled, Detecting Dementia: Emerging Innovations and Their Implications for American Adults and Their Health Care. Hosted by Tom Hubbard, Senior Vice President of Policy Research at NEHI, the virtual gathering will explore what these innovations mean for clinical practice and health care policy, a subject NEHI has covered in depth in a recent report.
On October 21, 2024 at 11:30 am PT, Elli will be in Las Vegas for the annual HLTH conference as part of a panel discussion called Brainiacs. Abby Miller Levy, Managing Partner and Co-Founder of Primetime Partners, will guide Kaplan and other tech and healthcare leaders in a discussion of new brain health innovations, including cutting-edge diagnostics, personalized treatment plans, and care models that adapt to the needs of aging adults. This will be Elli’s third speaking engagement at HLTH.
Elli, who lost two grandparents to Alzheimer’s disease, began Neurotrack with a team of neuroscientists in 2012, determined to leverage new technology to revolutionize cognitive screening. "It is an honor to be a part of these conversations with leaders in this field, and a thrill to finally be in this moment where the latest technology and therapeutic developments bring us ever closer to a day when Alzheimer’s and other dementias become manageable chronic conditions,” she says.
Neurotrack’s clinical solutions are in use with healthcare organizations from coast to coast, and the company recently added a variety of decision support features to their offering. Elli explains, “We are laser focused on supporting the primary care providers using our tools. Experts agree there aren’t enough specialists to close detection gaps, so PCPs must take up this challenge, but many lack the confidence to diagnose dementia. Now our platform prompts them to follow established best practices so those critical next steps will become second nature, and they can diagnose and triage patients without further delay.”
Neurotrack is a digital health company on a mission to transform the diagnosis and management of dementia and Alzheimer's disease. The company develops turnkey tools for providers that can be easily delivered at scale to facilitate early detection of cognitive impairment and ongoing monitoring of cognitive function. Neurotrack's patient-guided, clinically-validated assessments work in the clinic or at home to fit any workflow. The company also provides decision support for providers, as well as patient education to address modifiable risk factors. Neurotrack has published 25 peer-reviewed papers, holds 11 patents on its proprietary technology, and is registered as an FDA Class II medical device. Its solutions have been recognized by leading organizations including the Cleveland Clinic and the National Institute on Aging. Learn more at Neurotrack.
Elli Kaplan is the Co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including leadership positions at the White House, State and Treasury Departments, and the United Nations, where she was the Deputy Chief of Staff for UNDP, the largest UN agency. She was recently recognized as a leader in the area of innovation on Chief’s 2024 “Top 50 Executives” list. She’s also been part of San Francisco Business Chronicle’s “Most Influential Women in the Bay Area,” received SXSW’s “Best New Start-up,” and “DEMO God” awards, and won the Johnson & Johnson World Without Disease Challenge. Ms. Kaplan has presented at HLTH, Code, Fortune Health, TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the The New York Times. She has an MBA from Harvard Business School.